7-Methylguanosine 5'-triphosphate - patents, research & applications

462Patents

63Research papers

53Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	European Molecular Biology Laboratory	30
2	Caribou Biosciences Inc	24
3	Translate Bio Inc	19
4	Incyte Corp	17
5	ModernaTx Inc	13

6	Nestec SA	13
7	F Hoffmann La Roche AG	11
8	Agency for Science, Technology and Research	10
9	Beam Therapeutics Inc	9
10	Cocrystal Pharma Inc	9

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61K`	Medicinal preparations	262
2	`C12N`	Microorganisms, enzymes	257
3	`A61P`	Therapeutic activity (drug indications)	242
4	`C07K`	Peptides	173
5	`G01N`	Investigating / analysing materials	67

6	`C12Y`	Enzyme nomenclature (EC numbers)	62
7	`C07D`	Heterocyclic compounds	56
8	`Y02A`	Climate change adaptation	56
9	`C12Q`	Measuring/testing involving enzymes	46
10	`C12P`	Fermentation, enzyme processes	40

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#	Research topic	Papers
1	Influenza Virus Research Studies	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Edward Darżynkiewicz	University of Warsaw	7
2	Dixie J. Goss	Hunter College	5
3	Jacek Jemielity	University of Warsaw	5
4	Robert E. Rhoads	New York University	5
5	Janusz Stȩpiński	University of Warsaw	4

6	Joanna Zuberek	University of Warsaw	4
7	Joanna Kowalska	University of Warsaw	3
8	Ryszard Stolarski	University of Warsaw	3
9	Achim Dickmanns	University of Göttingen	2
10	Anna Niedźwiecka	University of Warsaw	2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events	2005	1251	RNA and protein synthesis mechanisms
The structural basis for cap binding by influenza virus polymerase subunit PB2	2008	489	Influenza Virus Research Studies
Biophysical Studies of eIF4E Cap-binding Protein: Recognition of mRNA 5′ Cap Structure and Synthetic Fragments of eIF4G and 4E-BP1 Proteins	2002	384	PI3K/AKT/mTOR signaling in cancer
Identification of a protein linked to the genomic and subgenomic mRNAs of feline calicivirus and its role in translation.	1997	164	Viral gastroenteritis research and epidemiology
The 5′-7-Methylguanosine Cap on Eukaryotic mRNAs Serves Both to Stimulate Canonical Translation Initiation and to Block an Alternative Pathway	2010	154	RNA and protein synthesis mechanisms

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of 7-Methylguanosine 5'-triphosphate?

7-Methylguanosine 5'-triphosphate has the molecular formula C11H18N5O14P3 and a molecular weight of 537.2073. Its canonical IUPAC name is [[[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate.

Which organizations hold the most patents involving this compound?

The leading patent assignees are European Molecular Biology Laboratory with 30 patents, Caribou Biosciences Inc with 24 patents, and Translate Bio Inc with 19 patents. Other significant assignees include Incyte Corp, ModernaTx Inc, and Nestec SA, each holding between 13 and 17 patents.

What research institutions are most active in publishing work on this compound?

Researchers from the University of Warsaw are particularly prominent, including Edward Darżynkiewicz with 7 papers, Jacek Jemielity and Janusz Stȩpiński with 5 and 4 papers respectively, and Joanna Zuberek, Ryszard Stolarski, and Anna Niedźwiecka with 4, 3, and 2 papers respectively. Other contributors include Dixie J. Goss from Hunter College and Robert E. Rhoads from New York University.

What are the primary research topics associated with this compound?

Published research focuses on RNA and protein synthesis mechanisms, influenza virus research, eIF4E cap-binding protein recognition, viral gastroenteritis, and the role of 5′-7-methylguanosine caps in translation initiation. A highly-cited 2010 paper on RNA and protein synthesis mechanisms received 154 citations, while a 2008 study on influenza virus polymerase cap binding received 489 citations.

How has patent activity for this compound evolved in recent years?

Patent filings have grown significantly, with 17 patents filed in 2016 increasing to 44 patents in 2021. The trend shows substantial activity in 2019–2024, with 24–38 patents filed annually. In the last three years (approximately 2022–2024), there have been 53 total patents filed. Over the entire period covered, there are 462 total patents in the database.